MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596690 | Name: L 738167

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L 738167 is a potent and long-acting fibrinogen receptor antagonist.

Chemical Structure

L 738167
L 738167
CAS#163212-43-9

Theoretical Analysis

MedKoo Cat#: 596690

Name: L 738167

CAS#: 163212-43-9

Chemical Formula: C25H34N6O6S

Exact Mass: 546.2261

Molecular Weight: 546.64

Elemental Analysis: C, 54.93; H, 6.27; N, 15.37; O, 17.56; S, 5.86

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
L 738167; L-738167; L738167;
IUPAC/Chemical Name
(S)-2-((4-methylphenyl)sulfonamido)-3-(4-oxo-5-(2-(piperidin-4-yl)ethyl)-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine-2-carboxamido)propanoic acid
InChi Key
YLFFZEQHDMFOEC-NRFANRHFSA-N
InChi Code
InChI=1S/C25H34N6O6S/c1-17-3-5-19(6-4-17)38(36,37)29-21(25(34)35)16-27-23(32)20-15-22-24(33)30(12-2-13-31(22)28-20)14-9-18-7-10-26-11-8-18/h3-6,15,18,21,26,29H,2,7-14,16H2,1H3,(H,27,32)(H,34,35)/t21-/m0/s1
SMILES Code
O=C(O)[C@H](CNC(C1=NN2C(C(N(CCC3CCNCC3)CCC2)=O)=C1)=O)NS(=O)(C4=CC=C(C)C=C4)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 546.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bednar B, Cook JJ, Holahan MA, Cunningham ME, Jumes PA, Bednar RA, Hartman GD, Gould RJ. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood. 1999 Jul 15;94(2):587-99. PubMed PMID: 10397726. 2: Bray ML, Jahansouz H, Kaufman MJ. Selection of optimal hydrate/solvate forms of a fibrinogen receptor antagonist for solid dosage development. Pharm Dev Technol. 1999 Jan;4(1):81-7. PubMed PMID: 10027216. 3: Bednar RA, Gaul SL, Hamill TG, Egbertson MS, Shafer JA, Hartman GD, Gould RJ, Bednar B. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets. J Pharmacol Exp Ther. 1998 Jun;285(3):1317-26. PubMed PMID: 9618439. 4: Cook JJ, Glass JD, Sitko GR, Holahan MA, Stupienski RF 3rd, Wallace AA, Stump GL, Hand EL, Askew BC, Hartman GD, Gould RJ, Lynch JJ Jr. Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury. Circulation. 1997 Aug 5;96(3):949-58. PubMed PMID: 9264506. 5: Askew BC, Bednar RA, Bednar B, Claremon DA, Cook JJ, McIntyre CJ, Hunt CA, Gould RJ, Lynch RJ, Lynch JJ Jr, Gaul SL, Stranieri MT, Sitko GR, Holahan MA, Glass JD, Hamill T, Gorham LM, Prueksaritanont T, Baldwin JJ, Hartman GD. Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists. J Med Chem. 1997 Jun 6;40(12):1779-88. PubMed PMID: 9191954. 6: Cook JJ, Sitko GR, Holahan MA, Stranieri MT, Glass JD, Askew BC, McIntyre CJ, Claremon DA, Baldwin JJ, Hartman GD, Gould RJ, Lynch JJ Jr. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation. J Pharmacol Exp Ther. 1997 May;281(2):677-89. PubMed PMID: 9152373. 7: Prueksaritanont T, Gorham LM, Naue JA, Hamill TG, Askew BC, Vyas KP. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics. Drug Metab Dispos. 1997 Mar;25(3):355-61. PubMed PMID: 9172954.

View History

S 1688

S 1688